A year after 5-hydroxymethylcytosine’s (5-hmC) dramatic entrance into the epigenetics research scene, the research community has a long list of questions to ask about the 6th base. Investigations into 5-hmC were sidelined for most of the year due to the absence of methods to analyze it. Thankfully those helpless days are history as Diagenode just launched the first 5-hmC mononclonal antibody, an innovation that makes enriching and analyzing 5-hmC a reality.
The new 5-hmC antibody from Diagenode is clingier than spandex without all the awkwardness, making it ideal for use in enrichment assays, like hydroxy MeDIP (hMeDIP), to isolate hydroxymethylated fragments.
Splitting Pairs of Cytosine Modifications Improves Your Odds
Sometimes one pull down isn’t enough. Diagenode’s Dual MeDIP Assay first uses the 5-hmC monoclonal antibody in hMeDIP. The unbound fraction is then run through the Diagenode monoclonal MeDIP Assay to grab all the 5-mC regions as well. You’re left with 5-hmC, 5-mC and unbound fractions and the ability to profile both types of cytosine marks in one experiment.
Don’t confuse this with an Atari game. This monoclonal means business.
Covering All the QC Angles
Unlike some antibody suppliers that will perform standard characterization approaches for antibody QC, Diagenode and its collaborators ran the 5-hmC antibody through the usual approaches (Dot Blot, Immunofluorescence, etc.,) but also performed functional testing including hMeDIP/hMeDIP-Seq, so that you don’t have to worry. They even offer 5-hmC control DNA so that you can keep tabs on its performance in every experiment.
Cash In With 5-hmC Profiling
If you’re ready to start churning out hydroxymethylcytosine data that you can take to the bank, check out Diagenode’s 5-hmC antibodies today.